Intuitive Surgical
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 09:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 8-K | 2026-11-02 | Read on SEC.gov |
| 10-Q | 2026-10-21 | Read on SEC.gov |
| 8-K | 2026-10-20 | Read on SEC.gov |
| 8-K | 2026-07-27 | Read on SEC.gov |
| 10-Q | 2026-07-21 | Read on SEC.gov |
| 8-K | 2026-07-16 | Read on SEC.gov |
| 8-K | 2026-05-28 | Read on SEC.gov |
| 8-K | 2026-05-04 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-22 03:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $10.06B | Annual | 2025-12-31 | 2026-02-03 | 10-K |
| Net income | $2.86B | Annual | 2025-12-31 | 2026-02-03 | 10-K |
| Operating cash flow | $3.03B | Annual | 2025-12-31 | 2026-02-03 | 10-K |
| Total assets | $20.46B | As of | 2025-12-31 | 2026-02-03 | 10-K |
| Total liabilities | $2.52B | As of | 2025-12-31 | 2026-02-03 | 10-K |
| Stockholders’ equity | $17.82B | As of | 2025-12-31 | 2026-02-03 | 10-K |
| Cash and cash equivalents | $3.37B | As of | 2025-12-31 | 2026-02-03 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 34.88, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Instruments and accessories is the largest reported line at 58.96% of revenue, across 3 reported segments.
- Systems follows at 25.23%, so the top line still matters most but isn’t the whole story.
Revenue annual, last 8 years
Latest year +20.51% YoY
Margins
- Gross margin
- 66.00%
- Operating margin
- 29.27%
- Net margin
- 28.38%
Key ratios & quality
- PEG ratioi
- 1.65
- Altman Z-Scorei
- 34.88
PEG uses trailing P/E against the 3-year net income growth rate (29.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.72B | 4.48B | 4.36B | 5.71B | 6.22B | 7.12B | 8.35B | 10.06B |
| Gross profit | 2.60B | 3.11B | 2.86B | 3.96B | 4.20B | 4.73B | 5.63B | 6.64B |
| Selling & admin expenses | 986.60M | 1.18B | 1.22B | 1.47B | 1.74B | 1.96B | 2.14B | 2.39B |
| Research & development | 418.10M | 557.30M | 595.10M | 671.00M | 879.00M | 998.80M | 1.15B | 1.31B |
| Operating profit | 1.20B | 1.37B | 1.05B | 1.82B | 1.58B | 1.77B | 2.35B | 2.95B |
| Pretax profit | 1.28B | 1.50B | 1.21B | 1.89B | 1.61B | 1.96B | 2.67B | 3.31B |
| Tax | 154.50M | 120.40M | 140.20M | 162.20M | 262.40M | 141.60M | 336.30M | 434.80M |
| Net profit | 1.13B | 1.38B | 1.07B | 1.73B | 1.34B | 1.82B | 2.34B | 2.88B |
| Basic EPS | 3 | 4 | 3 | 5 | 4 | 5 | 7 | 8 |
| Diluted EPS | 3.16 | 3.85 | 2.94 | 4.66 | 3.65 | 5.03 | 6.42 | 7.87 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 2.44B | 2.51B | 2.87B | 2.77B | 2.89B | 3.05B |
| Gross profit | 1.62B | 1.66B | 1.90B | 1.83B | 1.96B | 2.08B |
| Selling & admin expenses | 561.20M | 573.30M | 687.10M | 613.30M | 617.90M | 633.40M |
| Research & development | 313.30M | 329.40M | 352.90M | 361.90M | 370.60M | 408.30M |
| Operating profit | 743.40M | 759.70M | 864.30M | 855.30M | 971.90M | 1.04B |
| Pretax profit | 832.10M | 855.20M | 955.60M | 940.40M | 1.05B | 668.40M |
| Tax | 167.90M | 146.00M | 156.10M | 114.40M | 231.40M | 144.00M |
| Net profit | 664.20M | 709.20M | 799.50M | 826.00M | 823.20M | 524.40M |
| Basic EPS | 2 | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.81 | 1.95 | 2.21 | 2.28 | 2.29 | 1.49 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.33B | 4.66B | 6.63B | 5.84B | 6.25B | 7.89B | 7.11B | 9.78B |
| Cash & ST investments | 3.06B | 3.22B | 5.17B | 4.23B | 4.12B | 5.22B | 4.01B | 5.93B |
| Inventory | 409.00M | 595.50M | 601.50M | 587.10M | 893.20M | 1.22B | 1.49B | 1.84B |
| Total assets | 7.85B | 9.73B | 11.17B | 13.56B | 12.97B | 15.44B | 18.74B | 20.46B |
| Total current liabilities | 820.60M | 1.03B | 965.20M | 1.15B | 1.42B | 1.66B | 1.75B | 2.01B |
| Short-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,159,200,000.00 | 1,448,500,000.00 | 1,409,800,000.00 | 1,603,500,000.00 | 1,861,400,000.00 | 2,044,200,000.00 | 2,213,600,000.00 | 2,517,000,000.00 |
| Total equity | 6.69B | 8.28B | 9.76B | 11.95B | 11.11B | 13.40B | 16.53B | 17.94B |
| Retained earnings | 1.52B | 2.49B | 3.26B | 4.76B | 3.50B | 4.74B | 6.80B | 7.01B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 8.75B | 8.53B | 9.78B | 8.81B | 9.54B | 8.43B |
| Cash & ST investments | 5.33B | 4.91B | 5.93B | 4.52B | 5.22B | 4.04B |
| Inventory | 1.67B | 1.78B | 1.84B | 1.95B | 2.03B | 2.13B |
| Total assets | 20.16B | 19.35B | 20.46B | 20.11B | 20.88B | 19.35B |
| Total current liabilities | 1.69B | 1.80B | 2.01B | 1.91B | 1.92B | 2.53B |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,210,100,000.00 | 2,309,700,000.00 | 2,517,000,000.00 | 2,513,800,000.00 | 2,578,900,000.00 | 3,231,300,000.00 |
| Total equity | 17.95B | 17.04B | 17.94B | 17.60B | 18.30B | 16.12B |
| Retained earnings | 7.61B | 6.42B | 7.01B | 6.40B | 6.84B | 4.53B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.17B | 1.60B | 1.48B | 2.09B | 1.49B | 1.81B | 2.42B | 3.03B |
| Depreciation & amortization | 122.80M | 203.00M | 276.20M | 310.20M | 365.80M | 454.80M | 499.70M | 677.10M |
| Free cash flow | 982.20M | 1.17B | 1.14B | 1.75B | 958.40M | 749.60M | 1.30B | 2.49B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -269.50M | -134.30M | 0 | -2.61B | -416.30M | 0 | -2.30B |
| Ending cash balance | 909.40M | 1.18B | 1.64B | 1.31B | 1.60B | 2.77B | 2.06B | 3.41B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 715.40M | 841.00M | 892.50M | 911.90M | 1.06B | 1.22B |
| Depreciation & amortization | 164.40M | 169.60M | 193.50M | 200.00M | 231.10M | 212.90M |
| Free cash flow | 560.10M | 735.60M | 730.00M | 808.60M | 948.40M | 1.11B |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -181.00M | -1.91B | -201.00M | -1.12B | -320.30M | -2.98B |
| Ending cash balance | 3.45B | 2.85B | 3.41B | 2.05B | 2.81B | 3.02B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.78 | 18.46 | 11.79 | 15.76 | 11.53 | 14.77 | 15.62 | 16.67 |
| ROA %i | 16.58 | 15.69 | 10.15 | 13.79 | 9.97 | 12.66 | 13.59 | 14.57 |
| ROIC %i | 18.55 | 16.89 | 10.24 | 15.05 | 11.31 | 13.30 | 13.71 | 14.82 |
| 5-year avg ROE %i | 14.90 | 16.16 | 15.45 | 15.68 | 15.44 | 14.46 | 13.89 | 14.87 |
| EBIT margin %i | 32.21 | 30.69 | 24.09 | 31.89 | 25.35 | 24.80 | 28.12 | 29.27 |
| FCF / sales %i | 26.37 | 26.18 | 26.23 | 30.40 | 15.40 | 10.52 | 15.61 | 24.75 |
| Current ratioi | 5.28 | 4.53 | 6.86 | 5.08 | 4.40 | 4.76 | 4.07 | 4.87 |
| Quick ratioi | 4.56 | 3.81 | 6.11 | 4.46 | 3.65 | 3.91 | 3.08 | 3.77 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 16.02 | 18.28 | 11.57 | 15.31 | 11.58 | 17.80 | 13.51 | 17.39 |
| Net income CAGR (3Y) %i | 24.19 | 23.16 | 16.49 | 14.76 | -1.40 | 19.24 | 10.86 | 29.26 |
| FCF CAGR (3Y) %i | 10.64 | 4.31 | 6.25 | 21.23 | -6.50 | -13.13 | -9.34 | 37.49 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | 16.02 | 16.90 | 16.67 | 17.23 | 17.43 | 17.97 |
| ROA %i | 14.17 | 14.81 | 14.57 | 15.15 | 15.30 | 15.28 |
| ROIC %i | 14.14 | 15.02 | 14.82 | 15.48 | 15.80 | 16.30 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 28.80 | 29.30 | 29.27 | 30.45 | 31.28 | 32.25 |
| FCF / sales %i | 21.81 | 23.63 | 24.75 | 26.78 | 29.21 | 31.08 |
| Current ratioi | 5.17 | 4.73 | 4.87 | 4.61 | 4.96 | 3.33 |
| Quick ratioi | 3.97 | 3.49 | 3.77 | 3.26 | 3.64 | 2.32 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.
Intuitive Surgical discussion 0 comments